feedback

Course Director

Kevin R. Flaherty, MD, MS
Kevin R. Flaherty, MD, MS

University of Michigan Health System
Ann Arbor, Michigan

Faculty

Lisa H. Lancaster
Lisa H. Lancaster, MD

Vanderbilt University Medical Center
Nashville, Tennessee

Fernando J. Martinez
Fernando J. Martinez, MD, MS

Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2017-Nov-30
Expiration Date:2018-Nov-29
Estimated Time for Completion:60 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

In this activity based on a recent live symposium that took place at the 2017 Annual Meeting of the American College of Chest Physicians (CHEST 2017) in Toronto, Ontario, a panel of experts in pulmonology discusses how to distinguish between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs) based on unique radiographic and pathologic features. The panel reviews clinical data and emerging regimens for IPF and progressive fibrosing ILD, and provides guidance on how to apply evidence-based recommendations to obtain an accurate diagnosis and optimize treatment of ILD in your clinical practice.

Upon completion of this activity, participants should be better able to:

  • Describe the radiographic and pathologic features that differentiate idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs)
  • Evaluate relevant clinical data with respect to novel combination therapy for IPF, and emerging regimens for progressive fibrosing ILD and scleroderma-related lung fibrosis
  • Apply evidence-based recommendations for the diagnosis and treatment of interstitial lung disease, including IPF

Target Audience

This activity has been designed to meet the educational needs of pulmonologists and other clinicians involved in the management of patients with ILD.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: November 30, 2017 - November 29, 2018
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Kevin R. Flaherty, MD, MS
Professor of Medicine
Department of Pulmonary & Critical Care
University of Michigan Health System
Ann Arbor, Michigan

Kevin R. Flaherty, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant for Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FibroGen, Inc.; Genzyme Corporation; ImmuneWorks; and Veracyte, Inc.
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd/Genentech, Inc.
Kevin R. Flaherty, MD, MS, does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

Faculty

Lisa H. Lancaster, MD
Medical Director Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis Program
Associate Professor of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Lisa H. Lancaster, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, Inc.
Advisory Board for Bellerophon Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; and Global Blood Therapeutics Inc. (Whole Blood Therapeutics).
Other Financial or Material Support from Bellerophon Therapeutics for steering committee. Also serves as a speaker for disease state presentations for Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, Inc.
Lisa H. Lancaster, MD, does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

Fernando J. Martinez, MD, MS
Chief, Division of Pulmonary and Critical Care Medicine
Bruce Webster Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York

Fernando J. Martinez, MD, MS, has a financial interest/relationship or affiliation in the form of:
Advisory Board for AstraZeneca; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Patara Pharma; Pearl Therapeutics, Inc.; ProterixBio, Inc.; and Zambon S.p.A.
Other Financial or Material Support from Bayer Corporation; Gilead; and Veracyte, Inc. in the form of steering committee. Serves on the data safety monitoring board for Biogen; Boehringer Ingelheim Pharmaceuticals, Inc.; and Genentech, Inc. Also serves as a speaker for disease state presentations for Boehringer Ingelheim Pharmaceuticals, Inc. and Novartis Pharmaceuticals Corporation.
Fernando Martinez, MD, MS, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: antibiotic Rx and N-acetylcysteine (NAC).

CME Reviewer

Howard J. Lee, MD
Institute for Respiratory and Sleep Medicine
Yardley, Pennsylvania

Howard J. Lee, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Chris Washburn, PhD
PVI, PeerView Institute for Medical Education

Chris Washburn, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2017, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.